Since then, the stock has put up a good fight but has been struggling to get back to $7 throughout the rest of its recent trading history. More importantly, share value immediately plunged back to about $7 just as quickly as it crested. Unfortunately, the mid-$20s is the highest value the stock ever hit, though its highest close was $17.42 (Sep 4, 2018). Viking Peaked Quickly, but Outlook is Strong Overall, MDGL leaped up by about 268.07% while VKTX jumped 74%. This time, Viking’s successful NASH trial led to Madrigal share value also taking a big step forward in the following days. So, in the same way, that encouraging parallel data for these two drugs boosted respective share prices for their developers in 2018, it is also doing now, apparently. Following the IPO, Viking Therapeutics' stock skyrocketed to $24 in less than eight weeks. With approximately 7.5 million shares of common stock available-at a total value of approximately $67.5 million, the VKTX IPO distilled down to about $9.00 per share. This data came amidst Viking Therapeutics' initial public option, which launched on June 7, 2018. Around the same time, Madrigal had also launched trials for its drug (again, MGL-3196 ) with similar success. Viking Hit The Ground Running and Remains In StrideĪs a matter of fact, it was the success and promise of VK2809 that caused VKTX stock to soar (more than 88%) in 2018. Still, NASH cases are rising and could soon be the leading reason for liver transplants, meaning the market for drugs like these could grow rather quickly. Both drugs may be effective, but their studies involved different patient groups, so the collective data is more comprehensive than it is specific. It is important to note that while both drugs from these companies address similar health issues-and while both showed impressive results-they are not ultimately interchangeable. More importantly, VK2809 demonstrated similarly strong results as MGL-3196 in its own respective trial. After all, Viking's own VK2809 is part of the same family of drugs as Madrigal's Resmetirom (or MGL-3196, as it is known generically). But while the trial definitely left a mark on Madrigal investors, Viking Therapeutics felt an upward push, mostly because the company could be a potential buyout candidate for the drug. Madrigal's remarkable NASH results sent their stock soaring (up more than 231% at the time of this writing). Accordingly, Madrigal plans to file a new drug application to approve the drug as a treatment for non-cirrhotic NASH with liver fibrosis. This is a potential new treatment for nonalcoholic steatohepatitis (NASH) and liver fibrosis. In the middle of December, Viking Therapeutics saw its stock jump after Madrigal Pharmaceuticals released its successful Phase 3 MAESTRO-NASH biopsy trial of Resmetirom. Viking Stock Leaps On Madrigal Pharma's Successful MAESTRO-NASH Trial
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |